After releasing unfavorable results from the Phase 2 portion of the EBO-301 study, AN2 Therapeutics has decided to cease the trial. This study examined the efficacy of epetraborole in conjunction with an optimized background regimen (OBR) for treating treatment-refractory Mycobacterium avium complex (MAC) lung disease.
Despite achieving its primary objective of validating a patient-reported outcome (PRO) tool, the Phase 2 part failed to demonstrate a significant difference in sputum culture conversion at Month 6, a crucial secondary endpoint. As a result, AN2 will discontinue the Phase 2 (80 patients) and Phase 3 (97 patients) portions of the EBO-301 trial.
Despite the setback, AN2 remains committed to its boron chemistry platform and ongoing pipeline programs. The company plans to prioritize its internal boron chemistry platform and accelerate research efforts in infectious diseases and oncology. Additionally, AN2 will implement a strategic restructuring to extend its cash runway through 2027, allowing it to focus on advancing its pipeline through various milestones.
AN2’s boron chemistry approach involves using boron’s ability to form reversible covalent bonds with biological targets. This approach offers potential advantages for targeting biological targets that have been difficult to inhibit using carbon-based molecules.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
